Abstract
Despite inconsistent findings from studies using diverse methodologies and populations, commercial genotyping services have been marketed which recommend specific ADHD treatments. We sought to examine the relationship between several candidate and metabolism genes (DAT1,Drd4, ADRA1, COMT, CYP2D6) and response in children who are treated with OROS methylphenidate (MPH) and atomoxetine (ATX) in a crossover study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
